NEW YORK, Jan. 31, 2018 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Tesaro, Inc. (NASDAQ:TSRO) who purchased shares between March 14, 2016 and January 12, 2018. The action, which was filed in the United States District Court for the District of Massachusetts, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) substantial undisclosed health risks, including anaphylaxis and anaphylactic shock, were associated with Tesaro's intravenous formulation of VARUBI (rolapitant); and (ii) as a result of the foregoing, Tesaro's shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages. On January 12, 2018, Tesaro announced it had updated the U.S. labeling of VARUBI (rolapitant) injectable emulsion packages after reports that some patients receiving the treatment experienced “Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions.”
Shareholders have until March 19, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sb/tesaro-inc?wire=3.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com


Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Samsung Electronics Shares Jump on HBM4 Mass Production Report
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 



